Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM), a leader in targeted radiotherapies, has announced its participation in the upcoming 37th Annual Roth Conference, scheduled for March 16th to 18th, 2025.
The company's management team will be available for one-on-one meetings with investors on March 17th and 18th. Interested investors can arrange meetings through their ROTH representative or by submitting a registration request at Roth2025Registration.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM), un leader nelle radioterapie mirate, ha annunciato la sua partecipazione alla prossima 37ª Conferenza Annuale di Roth, in programma dal 16 al 18 marzo 2025.
Il team di gestione dell'azienda sarà disponibile per incontri individuali con gli investitori il 17 e 18 marzo. Gli investitori interessati possono organizzare incontri tramite il loro rappresentante ROTH o inviando una richiesta di registrazione a Roth2025Registration.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM), un líder en radioterapias dirigidas, ha anunciado su participación en la próxima 37ª Conferencia Anual de Roth, programada del 16 al 18 de marzo de 2025.
El equipo de gestión de la empresa estará disponible para reuniones individuales con inversores el 17 y 18 de marzo. Los inversores interesados pueden organizar reuniones a través de su representante de ROTH o enviando una solicitud de registro a Roth2025Registration.
액티니움 제약 (NYSE AMERICAN: ATNM), 표적 방사선 치료의 선두주자인, 다가오는 제37회 로스 연례 회의에 참여한다고 발표했습니다. 회의는 2025년 3월 16일부터 18일까지 예정되어 있습니다.
회사의 경영진은 3월 17일과 18일에 투자자와의 개별 미팅을 위해 대기할 것입니다. 관심 있는 투자자는 ROTH 대표를 통해 미팅을 조정하거나 Roth2025Registration에 등록 요청을 제출할 수 있습니다.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM), un leader dans les radiothérapies ciblées, a annoncé sa participation à la prochaine 37e Conférence Annuelle de Roth, prévue du 16 au 18 mars 2025.
L'équipe de direction de l'entreprise sera disponible pour des réunions individuelles avec des investisseurs les 17 et 18 mars. Les investisseurs intéressés peuvent organiser des réunions par l'intermédiaire de leur représentant ROTH ou en soumettant une demande d'inscription à Roth2025Registration.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM), ein führendes Unternehmen im Bereich gezielter Radiotherapien, hat seine Teilnahme an der bevorstehenden 37. jährlichen Roth-Konferenz angekündigt, die vom 16. bis 18. März 2025 stattfindet.
Das Management-Team des Unternehmens wird am 17. und 18. März für Einzelgespräche mit Investoren zur Verfügung stehen. Interessierte Investoren können Meetings über ihren ROTH-Vertreter organisieren oder eine Registrierungsanfrage an Roth2025Registration senden.
- None.
- None.
Actinium management will be in attendance during the conference and will be available for 1-on-1 meetings on March 17th and 18th. Interested investors should contact their ROTH representative or submit a registration request at Roth2025Registration.
About Actinium Pharmaceuticals, Inc.
Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). Actimab-A has demonstrated potential activity in relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) including measurable residual disease (MRD) negativity with improved survival outcomes and is being advanced to a Phase 2/3 trial. In addition, Actinium is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. The first clinical trial under the CRADA will evaluate the triplet combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential strategic partner for in the
For more information, please visit: https://www.actiniumpharma.com/
Forward-Looking Statements
This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.
Investors:
investorrelations@actiniumpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-to-participate-at-the-37th-annual-roth-conference-302399382.html
SOURCE Actinium Pharmaceuticals, Inc.